The French haemophilia cohort: Rationale and organization of a long-term national pharmacosurveillance system

Haemophilia

Volumn 7, Issue 1, 2001, Pages 82-88

  Calvez, T ^a   Biou, M ^a   Costagliola, D ^a   Jullien, A M ^a   Laurian, Y ^a   Rossi, F ^a   Rothschild, C ^a   Sie P ^a  

^a INSERM   (France)

Author keywords

Clotting factor preparations; Cohort study; France; Haemophilia; Health watch policy; Pharmacoepidemiology

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ADOLESCENT; ADULT; ARTICLE; BLOOD BANK; BLOOD SAMPLING; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SURVEILLANCE PROGRAM; FOLLOW UP; FRANCE; HEALTH CARE POLICY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0035134654     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2001.00457.x     Document Type: Article

References (27)

1. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A
2. A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A
3. Recommendations for the treatment of factor VIII inhibitors: From the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party
4. Inhibitors in hemophilia A. are some products safer?
5. Why do inhibitors arise in patients with haemophilia A?
6. Incidence of inhibitors in haemophilia A patients - A review of recent studies of recombinant and plasma-derived factor VIII concentrates
7. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands
8. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate
9. Factor VIII inhibitors in previously treated Haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate
10. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII. C inhibitors in the haemophilia A population of Canada
11. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80. Report of behalf of the directors of haemophilia centres in the United Kingdom
12. Epideminology of hemophilia and of HIV infection in Italy
13. The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates
14. Human immunodeficiency virus infection due to clotting factor concentrates: Results of the Serocoversion Surveillance Project
15. Occurrence of hemophilia in the United States
16. Surveillance for bloodborne infections
17. World registry on factor VIII inhibitor patients: Why?
18. Factor VIII preparations: Need for prospective pharmacovigilance
19. High titer inhibitors in severe haemophilia A - A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products
20. Plasma-derived versus recombinant factor VIII for the treatment of hemophilia A
21. A post-marketing safety and efficacy assessment of a monoclonal anti-body purified high-purity factor VIII concentrate
22. Viral safety of plasma-derived factor VIII and IX concentrates
23. Prevention and control of haemophilia. Memorandum from a joint WHO/WFH meeting
24. Two decades of haemophilia treatment in the Netherlands 1972-92
25. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia
26. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy